biosyn Corporation

We Do Research!

Selenase® In Resuscitation

Scientific information On


Causes Of Ischaemia:

  • Cardiac / circulatory arrest due to:
  • Coronary heart disease/coronary infarction (70 – 80%)
  • Cardiomyopathy, myocarditis (10 – 15%)
  • Other causes

Risks After Reperfusion:

  • Specific damage to heart, lung and brain tissue
  • Hyperinflammation (= post resuscitation, sepsis-like syndrome)
  • Endothelial damage

Conventional Measures To Reduce Tissue Damage:

  • Cardiac massage (earliest possible)
  • Cardiac massage : ventilation → 30:2
  • Volume replacement, vasoactive substances → however, up to date not sufficiently effective

Data On Selenium (Selenite, Some With Selenase®):

  • SIRS / sepsis patients have low selenium levels, this correlates with the severity of the disease [Sakr et al. British Journal of Anaesthesia 98 (2007) 775-784]
  • Selenium supplementation reduces mortality in SIRS/sepsis patients (SIC) [Angstwurm et al. Crit Care Med 35 (2007) 1­9]
  • Selenium significantly improves neurological survival in patients with cardiac arrest [Reisinger et al. European Society of Cardiology (ESC) Congress Vienna 2007]
  • High doses of selenium (100 g/kg) protects from neurodegeneration (animal model) [Ansari et al. Biological Trace Element Research 101 (2004) 73-86]
  • High doses of selenium (100 g/kg) reduce cerebral cell death after ischaemia / reperfusion (animal model) [Yousuf et al. Brain Research 1141 (2007) 218-225] · Selenium levels are significantly reduced in patients after cardiac / circulatory arrest [Busch et al. DIVI (2008)]

Possible Actions Of Selenium Supplementation:

  • Reduction of tissue damage in heart, lungs and brain, i.e. improved neurological outcome
  • Prevention or minimisation of systemic inflammation (SIRS)

Suggested Timing And Dosage For Selenium Supplementation:

Time point Dosage
Bolus dose immediately upon transfer of the patient into ambulance 1000 g Se/d as selenase® solution for injection
Bolus dose on admission to catheter lab 1000 g Se/d as selenase® solution for injection
Continuous infusion over 4 days 1000 g Se/d as selenase® solution for injection

Information sheet on PLASTIC SURGERY, biosyn Arzneimittel GmbH, RSi 2008. According to a lecture given by Prof Dr med H Homann, Thieme Workshop 2008 entitled “Ischaemia and reperfusion an interdisciplinary challenge”. For personal use only.

Abbreviated Prescribing Information

selenase® 100 micrograms, solution for injection (50 micrograms/ml)
selenase® 500 micrograms, solution for injection (50 micrograms/ml)

  • Active ingredient: sodium selenite pentahydrate.
  • Composition: Each 2 ml ampoule/10 ml injection vial contains 100 micrograms/500 micrograms selenium as 333 micrograms/ 1.66mg sodium selenite pentahydrate (Na2SeO3 x 5H2O), corresponding to 50 micrograms/ml.
  • Excipients: Sodium chloride, hydrochloric acid, Water for Injections.
  • Indication: Proven selenium deficiency that cannot be offset from food sources.
  • Posology and Administration: selenase® solution for injection is administered as an intramuscular or intravenous injection at a daily dose of 100 ­ 200 g (1.27 ­ 2.53 mol) selenium. If necessary, this dose can be increased to 500 g (6.33 mol) for a typical adult. No dosage adjustment is required for paediatric, renal or hepatic impairment patients.
  • Contraindications: Selenosis.
  • Interactions: Ensure that the pH value does not fall below 7.0 and that the solution is not mixed with reducing substances (e.g. vitamin C).
  • Pregnancy and Lactation: There are no data from the use of selenase® in pregnant or lactating women.
  • Undesirable Effects: None known to date when used as directed.
  • Overdose: Counter measures include gastric lavage, forced diuresis, dialysis or administration of high doses of vitamin C.
  • Pharmaceutical Precautions: Store below 25ºC.
  • Legal Category: POM.
  • Presentation: Cartons containing 10 x 2ml ampoules / 10 x10ml glass vials for single use.
  • MA Numbers: PL 20437/0003, PL 20437/0004.
  • MA Holder: biosyn Arzneimittel GmbH, Schorndorfer Str 32, D-70734 Fellbach, Germany.
  • Date of Preparation: November 2004